Thursday's Health Winners & Losers
Clinical data and analyst speculation pushed a few biotech stocks up on Thursday while others fell in light of earnings.
Advanced Life Sciences rose after announcing positive results from Trial CL-05, the second of two pivotal phase III clinical trials assessing the safety and efficacy of cethromycin, a once-a-day antibiotic for mild-to-moderate community acquired pneumonia (CAP). The study results showed that cethromycin was non-inferior to Biaxin, a current standard-of-care treatment for CAP, and demonstrated favorable safety results, with reported side effects similar to or less than those seen with Biaxin.
The company said around 5.6 million cases of CAP are diagnosed each year in the U.S, resulting in an estimated total annual expenditure of $2 billion for prescribed antibiotics. CAP is potentially fatal if not treated properly, and the bacteria that cause CAP are developing resistance to current standard-of-care treatments. Shares edged up 8 cents, or 4.2%, to $1.98.Meanwhile, Amylin said that in a 24-week phase IIa study its drug candidate pramlintide in combination with metreleptin (which requires four daily injections -- two of each component) reduced the body weight of participants in a 177-patient study by an average of 12.7%, while treatment with pramlintide alone reduced body weight by 8.4%. However, only 139 of the 177 patients were eligible to participate in the last 20 weeks of the study. Shares were trading up $1, or 2.5%, at $42.06.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV